Cancer Immunotherapy

Genetically Engineered Lymphoma Cells Induce Immunity

Published in Cancer Weekly, August 16th, 1999

Genetic engineering of autologous B lymphoma cells to express idiotype and granulocyte macrophage-colony stimulating factor (GM-CSF) induced tumor immunity in three different models.

M. Selmayr and colleagues from Germany and Belgium developed a strategy to circumvent obstacles associated with using lymphoma idiotype (Id) to produce an engineered vaccine to treat B cell lymphoma ("Induction of Tumor Immunity by Autologous B Lymphoma Cells Expressing a Genetically Engineered Idiotype," Gene Therapy, 1999;6(5):778-84).

"We have developed a strategy that allows the expression of an Id/GM-CSF fusion protein in an autologous lymphoma cell," wrote Selmayr...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry